The goal of the Project is to develop affinity-directed drug conjugates based on the novel payload and to perform in vitro/in vivo studies using those conjugates. The payload with high cytotoxicity belongs to the anthracycline class of compounds and was previously developed by ToxInvent. The conductor of the study is Tartu University. During the Project the synthetic route leading to the payload will be optimized and then both the antibodies and nanoparticles will be used for conjugation with the payload. The outcome of the Project will be innovative drug candidates for targeted anticancer therapy. After the Project is accomplished the obtained drug candidates will be outlicensed to pharma companies for further development.
Duration: 01.09.2017 – 30.06.2021
The project is co-financed by the European Regional Development Fund with EUR 612 500.